PTO/SB/08A (10-96 Approved for use through 10/31/99, OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Substitute for form 1449A/PTO	ed to respond to a collection of information unless it contains a	Patent and Trademark Office: U.S. DEPARTMENT OF CC valid OMB control number
			Complete if Known
	INFORMATION DISCLOS	SURE Application Number	
	STATEMENT BY APPLIC	CANT	09/506,988
		•	1
10/	P cose as many sheets as necessa	rv)	
/		Filing Date	
JIH 9	8 2000 S	First Named Inventor	February 18, 2000
5	· All 7]	Group Art Unit	Jordan J.N. Tang
in the last of the		Examiner Name	1614
We _	of 6	Attorney Docket Number	
\$ THAD	EMARK		OMRF 176
xaminer's (	UITER	RART NON PATENT LITERATURE DOCUM	ENTS
Initials*   N	Vo.1 item (book, magazin	the author (in CAPITAL LETTERS), title of the article (in e, journal, serial, symposium, catalog, etc.), date, page	when appropriate) title of the
	DALDWIN	ne author (in CAPITAL LETTERS), title of the article ( ne, journal, serial, symposium, catalog, etc.), date, pay publisher, city and/or country where published	ge(s), volume-issue number(s)
	BALDWIN, et al., "Structural bas	publisher, city and/or country where published is of drug resistance for the V82A mutant o	ed
MX	2137:244-9 (1995).	o wasteriod for the VOZA mutant o	f HIV-1 proteinase," Nat. Struct. Biol.
-	BOGER "Regin Inhibited S		
1 1	restricted inhibitors and a model	of Angiotensinogen Transition-state Analog or the bound conformation of renin substrat	S Containing Stati
	Inhibitors, (Kostka, V. ed.), pp. 4	of Angiotensinogen Transition-state Analog or the bound conformation of renin substrat 01-420, Walter de Gruyter:N.Y., 1985.	e." in Aspartic Protein
	CARPENTER, et al., "Antiretrovira	or the bound conformation of renin substrat 01-420, Walter de Gruyter:N.Y., 1985.	Aspartic Proteinases and Their
11	AIDS Society-USA Panel," JAMA	01-420, Walter de Gruyter:N.Y., 1985. Il therapy for HIV infection in 1998: Updated 280(1):78-86 (1998).	recommendations of the Internation
	CARROLL	200(17.76-86 (1998).	of the international
11	CARROLL, et al. "Identification of	potent inhibitors of Plasmodium falsi	
11	Combinatorial library," Bioorg. Med	potent inhibitors of <i>Plasmodium falciparum</i> d. Chem. Lett. 8(17):2315-20 (1998).	plasmepsin II from an encoded statine
	CARROLL, et al. "Evaluation of		
- 11	plasmepsin II and cathensin D " Pi	structure-based statine cyclic diamino amide porg. Med. Chem. Lett. 8(22):3203-6 (1998	encoded combinatorial III
		Durg. Med. Chem. Lett. 8(22):3203-6 (1998	3).
- 11	CHEN, et al., "Three-dimensional	<del></del>	
- 11	inhibitors in clinical trials," J. Biol.	tructure of a mutant HIV-1 protease displays Chem. 270(37):21433-6 (1995).	ing cross-resistance to all protease
	COFFIN "HIV -		, 1545C
	267(5197):483-9 (1905)	in vivo: implications for genetic variation, p	athogo
	1 1977,700-9 (1990).	σ ····································	attriogenesis, and therapy," Science
	CONDRA, et al., "Genetic correlate	s of in vivo viral resistance to indinavir, a hu :8270-6 (1996).	
	protease inhibitor," J. Virol. 70(12)	8270 6 (1000)	ıman immunodeficiency visus to
<del>/   _</del>	10(12)	.0270-0 (1996).	virus type 1
/	CONDRA, et al., "In vivo emergence	of HIV-1 variants resistants	
/	3/4(6522):569-71 (1995).	e of HIV-1 variants resistant to multiple prot	ease inhibitors," Nature
1 1/2	Antiviral Res 16(4) 205 205	f Ro 31-8959, an inhibitor of human immus	odefi-
1	10(4):295-305 (1991)	of Ro 31-8959, an inhibitor of human immur	iodeficiency virus (HIV) proteinase,"
	•	<del></del>	1
er's	\n\ 0		
<u>~</u>	VI Keenon	Date Considered	<del></del>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of Translation is attached.

Translation is attached.

Please type a plus sign (+) inside this box $\rightarrow$	+	
	1 1	

Sheet

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1614

**OMRF 176** 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known

INFORMATION DISCLOSURE

Application Number

O9/506,988

Filling Date

Filling Date

First Named Inventor

Jordan J.N. Tang

**Group Art Unit** 

Examiner Name

Attorney Docket Number

6

		OMICE 176	
		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiners	Cite	Include name of the author (in CARITAL LETTERS) in the second of the author (in CARITAL LETTERS).	
Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country when authinted and item (something the country when a something the country	ΤŽ
	<u></u>	publisher gibt and/s calaing, etc.), date, page(s), volume-issue number(s),	•
		publisher, city and/or country where published  DEBOUCK & METCALF, "Human Immunodeficiency Virus Protease: A target for AIDS therapy," Drug Devel. Res.	
۱ ۸.		21:1-17 (1990)	
My 1		2.1. 17 (1000).	
		DEBOUOK	
\ I		DEBOUCK, et al., "Human immunodeficiency virus protease expressed in <i>Escherichia coli</i> exhibits autoprocessing and specific maturation of the gag precursor." <i>Proc. Natl. Acad. Sci. USA 84</i> , 2002, 2007, the processing and	
1 1		specific maturation of the gag precursor," <i>Proc. Natl. Acad. Sci. USA</i> 84:8903-8907 (1987).	
-			
1 1		DORSEY, et al., "I -735 524; the design of a second by	
1 1		DORSEY, et al., "L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor," <i>J. Med. Chem.</i>	
		110 01 (1004).	
		DUNN as all 100 h	
- 1 1		DUNN, et al., "Subsite preferences of retroviral proteinases," Methods Enzymol. 241:254-178 (1994).	
1 1		241.254-176 (1994).	
-++			
1 1	I	ERMOLIEFF, et al., "Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1	
1 1	l l	protease and their implications in drug registeries in the state mutants of human immunodeficiency virus type 1	
1 1	ı	protease and their implications in drug resistance in Vivo," Biochemistry 36(40):12364-70 (1997).	
		GHOSH at al. "2 total had a	
1 1	- 1.	GHOSH, et al., "3-tetrahydrofuran and pyran urethanes as high-affinity $P_2$ -ligands for HIV-1 protease inhibitors," <i>J.</i>	
1 1	ľ	Med. Chem. 36:292-94 (1993).	
$\longrightarrow$			
1 1	ľ	JHOSH, et al., "An efficient synthesis of hydroxyethylene dipentide inserting."	J
11	ji	GHOSH, et al., "An efficient synthesis of hydroxyethylene dipeptide isosteres: The core unit of potent HIV-1 protease nhibitors," J. Org. Chem. 56:6500-3 (1991)	
-		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	- 1
1 1	70	GRAVES. "Human immunodatiois says in	- 1
- 1	le	GRAVES, "Human immunodeficiency virus proteinase: now, then, what's next?" Adv Exp Med Biol. 306:395-405	-4
- 1	ľ	7.001/	
-+		NHAW Law	
I 1	- 10	GULNIK, et al., "Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug ressure," <i>Biochemistry</i> 34(29):9282-7 (1995).	
$I \perp I$	lb	ressure," Biochemistry 34(29):9282-7 (1995).	
		,	
'	H	O, et al., "Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection," <i>Nature</i> 373(6510):123-6	Į
Land	le:	1995).	$\dashv$
וא יוע	ľ		
			1

Examiner's Signature Date Considered 7 Jent 2000

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language

Please type a plus sign (+) inside this box →	+	1

PTO/SB/08A (10-96	
Approved for use through 10/31/99, OMB 0651-0031	
ent and Trademark Office: U.S. DEPARTMENT OF COMMEDCE	

the Paperwork Reduction Act of 1995, no persons are required to respond to Substitute for form 1449A/PTO		and Chilb Curius Humber
	C	omplete if Known
INFORMATION DISCLOSURE O STATEMENT BY APPLICANT (use es many sheets as necessary)	Application Number	09/506,988
	Filing Date	February 18, 2000
Of 6	First Named Inventor	Jordan J.N. Tang
Eller State	Group Art Unit	1614
PADEMIN OF	Examiner Name	
01 6	Attorney Docket Number	OMRF 176

Examiner's	Cito	OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS) title of the article (in	<del></del>
midais	NO.	I Catalog et al. (a) Volume inque et al. (a)	T*
			1
. ^		DUNN, et al., "Subsite Preferences of Retroviral Proteinases" Methods in Enzymology 241:254-278 (1994).	1
3/V) / I		Wethous III Enzymology 241:254-278 (1994).	
0 1			1
$\neg$		HONG et al. "Active eite mobility in	1
\ 1		HONG, et al., "Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant," <i>Protein Sci.</i> 7(2):300-5 (1998)	<del>                                     </del>
1 1		structure of A28S mutant," <i>Protein Sci.</i> 7(2):300-5 (1998).	ı
-+			[
1 1		HONG, et al., "Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1	
1 1	j	proteases," Biochemistry 35:123-126 (1996).	
1 1	ŀ	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	1
		HOOVER at all MD	1
1 1	- 1	HOOVER, et al., "Discovery of inhibitors of human renin with high oral bioavailability," Adv Exp Med Biol. 362:167-	
- 1 1	- 1	50 (1995).	
-			
1 1	ļ.	DO, et al., "Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S," J. Biol. Chem. 266(36):24359-66 (1991)	
1 1	l,	mutant A28S," J. Biol. Chem. 266(36):24359-66 (1991).	
	- 1	200(30):24359-66 (1991).	
	-+	ACORSEN as all 40	
1 1		ACOBSEN, et al., "Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to	
1 1	ļ.	proteinase inhibitor Ro 31-8959," Virology 206(1):527-34 (1995).	
1 1	-	ACOBSEN, et al., "In vivo resistance to a human immunodeficiency."	
1 1	lk	ACOBSEN, et al., "In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, inetics, and frequencies," <i>J. Infect. Dis.</i> 173(6):1379-87 (1996).	
		173(6):1379-87 (1996).	
	- k	EMPE at al. "APT FOO	
1 1	I.	EMPF, et al., "ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral	
1 1	lo In	ioavailability in humans," Proc. Natl. Acad. Sci. U S A. 92(7):2484-8 (1995).	
1 1	Įκ	OHL, et al., "Active human immunodeficiency virus protease is required for viral infectivity," Proc. Natl. Acad. Sci.	
1 1	U	SA 85(13):4686-90 (1988).	
		1 2/1000/1	
1,+	<del>-  </del> -	APATTO et al. #V	
161	1	APATTO, et al., "X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among	
MM	إre	etroviral enzymes," Nature 342(6247):299-302 (1989).	1
1/ B			- 1

Examiner's		
1		
Signature Think Oww	Date Considered	1/2
The polon	1 1/8	#- K1
		441 ng
*EVAMINED: 1-10-Year	<del>- 0 -</del>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of Cocument by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →	+

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO	The state of the s	and OMB control number
	Co	omplete if Known
INFORMATION DISCLOSURE  STATEMENT BY APPLICANT  (use as many sheets as necessary)	Application Number	09/506,988
<b>3 8 2000</b> E.	Filing Date	February 18, 2000
	First Named Inventor	Jordan J.N. Tang
<b>\</b>	Group Art Unit	1614
No.	Examiner Name	
neet the TRADE	Attorney Docket Number	OMRF 176

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
Mus		LIN, et al., "Effect of point mutations on the kinetics and the inhibition of human immunodeficiency type 1 protease: Relationship to drug resistance," <i>Biochemistry</i> 34:1143-1152 (1995).	
		MAJER, et al., "Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors," Protein Sci. 6(7):1458-66 (1997).	
		MARCINISZYN, et al., "Mode of inhibition of acid proteases by pepstatin," J. Biol. Chem. 251(22):7088-94 (1976).	
		MELLORS, "Closing in on human immunodeficiency virus-1," Nat. Med. 2(3):274-5 (1996).	
		MOLLA, et al., "Ordered accumulation of mutations in HIV protease confers resistance to ritonavir," <i>Nat. Med.</i> 2(7):760-6 (1996).	_
		MULICHAK & WATENPAUGH, "The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors," J. Biol. Chem. 268(18):13103-9 (1993).	<u>-</u> -
	7	NAVIA, et al., "Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1," <i>Nature</i> 337(6208):615-20 (1989).	
	ļ	PATICK, et al., "Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human mmunodeficiency virus protease," <i>Antimicrob. Agents Chemother.</i> 40(2):292-7 (1996).	
	F	PENG, et al., "Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity," J. Virol. 63(6):2550-6 (1989).	
BAX	F	POORMAN, et al., "A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, offerred from statistical analysis of an extended substrate data base," J. Biol. Chem. 266(22):14554-61 (1991).	

Examiner's Signature MM & Owo	Date Considered - Jun 110
*EYAMINED Initial if or formand	TO WILL

MINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language

Please type a plus sign (+) inside this box →	$\Box$	
	1 1	

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond  Substitute for form 1449A/PTO	to a collection of information values in	Approved for use through 10/31/99. OMB 0651-003 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC
Substitute for form 1449A/PTO	Tonication of million and unless it contains a v	valid OMB control number
INFORMATION		Complete if Known
INFORMATION DISCLOSURE PESTATEMENT BY APPLICANT  (Luste as many sheets as necessary)	Application Number	09/506,988
	Filing Date First Named Inventor	February 18, 2000
The state of the s	Group Art Unit	Jordan J.N. Tang
Sherry Och	Examiner Name	1614
Show TRADE of 6	Attorney Docket Number	OMRF 176
Fyaminer's Light OTHER ART - N	ION PATENT LITERATURE DOCUM	ENTO

		OMRF 176
	-	OTHER ART ~ NON PATENT LITERATURE DOCUMENTS
Examiner's Initials*	Cite No.1	
ililiais	140.	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),
		The state of the s
- 1. NC		RIDKY & LEIS, "Development of drug resistance to UNA"
412 X		RIDKY & LEIS, "Development of drug resistance to HIV-1 protease inhibitors," J. Biol. Chem. 270(50):29621-3
1.	_	
Ī		RIDKY, et al. "Human improved of
- 1		RIDKY, et al., "Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme substrate." In Pict Chapter 1975.
1 1		between substrate amino acids bound in adjacent enzyme subsites," J. Biol. Chem. 271:4709-4717 (1996).
		POCULTODS: 171.4/09-4/17 (1996).
1 1		NOCHEFORI, "Biological and clinical significance of cathensin D in broads and clinical significance of cathensin D. in broads and cathensin D. in broads and clinical significance of cathensin D. in broads and cat
1 1		ROCHEFORT, "Biological and clinical significance of cathepsin D in breast cancer," Semin. Cancer Biol. 1(2):153-60
1 1	ł	ROSE, et al., "Human immunodeficiency virus transfer.
	ŀ	ROSE, et al., "Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors," <i>Proc. Natl. Acad. Sci. USA</i> 93(4):1648-53 (1996)
		to protease inhibitors," <i>Proc. Natl. Acad. Sci. USA</i> 93(4):1648-53 (1996).
T		
1 1	[,	SCHNEIDER & KENT, "Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1
] ]	ľ	**************************************
$\rightarrow$		CIAAAAI
1 1		onwian, et al., "Processing of the beta-amyloid precursor. Multiple protection."
1 1	٥	SIMAN, et al., "Processing of the beta-amyloid precursor. Multiple proteases generate and degrade potentially imyloidogenic fragments," <i>J. Biol. Chem.</i> 268(22):16602-9 (1993).
+-+	,	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1	ĮS	ZELKE, "Chemistry of Renin Inhibitors" in Assertic D.
1 1	10	Walter de Gruyter:N.Y., 1985).
I = T	T	ANG & HARTSUCK "A kingsin
1 1	lo	ANG & HARTSUCK, "A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential f mutant HIV-1 proteases," FEBS Lett. 367(2):112-6 (1995).
1 1	ľ	f mutant HIV-1 proteases," FEBS Lett. 367(2):112-6 (1995).
$\vdash$		
1	- 1'	OH, et al., "Is the AIDS virus recombinant?" Nature 316(6023):21-2 (1985).
1		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
<del>  </del>		
. 🚺	TC	DMASSELLI, et al., "The complexities of AIDS: An assessment of the HIV protease as a therapeutic target,"
\/\ X	C	himicaoggi-Chemistry Today 9:6-27 (1991).

Examiner's Signature Date Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of Translation is attached. <sup>6</sup> Applicant to place a check mark here if English language

Please type a plus sign (+) inside this box →	+	

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE Application Number 09/506,988 TATEMENT BY APPLICANT many sheets as necessary) Filing Date February 18, 2000 First Named Inventor Jordan J.N. Tang **Group Art Unit** 1614 **Examiner Name** Sheel 6 Attorney Docket Number **OMRF 176** WATT & TO OTHER ART - NON PATENT LITERATURE DOCUMENTS Examiner's Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials\* No. publisher, city and/or country where published TONG, et al., "Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced

parison with HIV-1 protease structures," Proc. Natl. Acad. Sci. USA 90(18):8387-91 (1993).
onal characterization of the protease of human endogenous retrovirus, K10: can it ase?" Biochemistry 37(49):17137-44 (1998).
t-Binding Human Immunodeficiency Virus Type 1 Protease Inhibitors," Methods in 4 (1994).
ics in human immunodeficiency virus type 1 infection," Nature 373(6510):117-22 (1995).
or Viruses, Cold Spring Harbor:NY, 1984.
N, "Structure-based inhibitors of HIV-1 protease," Annu. Rev. Biochem. 62:543-85 (1993).
nserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease," 21 (1989).

Examiner's Signature	Date Considered 7 Ap At (N)
VI	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.